LV Endocardial Cardiac Resynchronisation Therapy
Launched by ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST · Jun 24, 2014
Trial Information
Current as of June 12, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age greater than 18 years
- • NYHA class II-IV
- • LVEF ≤35%
- • QRS ≥120 milliseconds
- • Optimal tolerated medical therapy
- • Either unable to position an LV lead via the standard coronary sinus on CRT implantation
- • OR Recipient of a CRT-P or CRT-D system for greater than 6 months for standard indications AND limited improvement or worsened clinical status despite device optimisation
- • Informed consent
- Exclusion Criteria:
- • Life-expectancy less than 1 year due to concomitant, non-cardiovascular disorders
- • Previous atrial septal defect device closure.
- • Chronic renal dialysis and End stage liver disease
- • History of stroke, myocardial infarction, unstable angina, Coronary artery bypass grafting and coronary stenting within the last 3 months
- • Presence of correctable valvular disease (aortic/mitral)
- • Mitral valve prosthesis.
- • Contra indication to vitamin K antagonist
- • Unresolved intra-cardiac thrombus
- • Pregnancy
About Royal Brompton & Harefield Nhs Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust is a leading specialist healthcare provider in the United Kingdom, renowned for its expertise in cardiothoracic medicine and respiratory care. Committed to advancing clinical research and improving patient outcomes, the Trust conducts a diverse range of clinical trials aimed at exploring innovative treatments and therapies. With a multidisciplinary team of clinicians and researchers, the Foundation Trust fosters a collaborative environment that prioritizes patient safety and ethical standards, contributing significantly to the global body of medical knowledge and enhancing the quality of care for patients with complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Tom Wong, MD FESC
Principal Investigator
Royal Brompton and Harefield NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials